Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

Exclusion Criteria

• •Evidence of ischemic heart disease as determined by study cardiologist
• •Significant valvular disease; (aortic stenosis \[AS\] with aortic valve area \[AVA\] \< 1.5 and severe aortic regurgitation \[AR\] and mitral regurgitation \[MR\])
• •History of familial cardiomyopathy
• •Recent documented myocarditis within 2 months of consent
• •History of infiltrative cardiomyopathy or restrictive cardiomyopathy
• •Epidermal growth factor receptor (eGFR) \< 50 by Mayo or Cockcroft formula
• •Liver function tests \> 3 x upper limit of normal
• •NYHA class IV heart failure
• •Inotropic dependence
• •Unstable or life-threatening arrhythmia
• •Coagulopathy international normalized ratio (INR) \> 1.5
• •Mechanical or bioprosthetic heart valve
• •Cardiogenic shock
• •Breast feeding and/or pregnant women
• •Autoimmune disorders on current immunosuppressive therapy
• •Active infection not responding to appropriate therapy as determined by study chair
• •Trastuzumab treatment within the last 3 months